Managers / Q2 2021 · view latest →
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
CIK 0001047859 · 500 CRESCENT COURT, SUITE 260, DALLAS, TX, 75201 · 2148713700
Summary
Paragon Associates & Paragon Associates II Joint Venture reported $75M in U.S.-listed holdings across 16 positions for Q2 2021.
Its largest position, NVGS, represents 18.4% of the portfolio.
Compared with Q1 2021, the fund opened 6 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.8% · $70M
- ETP · 5.7% · $4M
- REIT · 1.5% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MLKNMILLER HERMAN INC | NEW | +165.0K | 165.0K | +$8M | $8M |
| CREDIT SUISSE GROUP | NEW | +300.0K | 300.0K | +$3M | $3M |
| EXECHESAPEAKE ENERGY CORP | NEW | +53.0K | 53.0K | +$3M | $3M |
| KNLKNOLL INC | NEW | +50.0K | 50.0K | +$1M | $1M |
| BFSSAUL CTRS INC | NEW | +25.0K | 25.0K | +$1M | $1M |
| LUMOS PHARMA INC | NEW | +50.0K | 50.0K | +$500,000 | $500,000 |
| EEFTEURONET WORLDWIDE INC | SOLD OUT | −7.5K | 0 | −$1M | $0 |
| NEMNEWMONT CORP | TRIMMED | −135.0K | 65.0K | −$8M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | NVGSNAVIGATOR HLDGS LTDhistory → | SHS | 18.36% | $14M | 1.26M |
| 2 | REATA PHARMACEUTICALS INC | CL A | 12.82% | $10M | 68.1K |
| 3 | MLKNMILLER HERMAN INChistory → | COM | 10.35% | $8M | 165.0K |
| 4 | IRIXIRIDEX CORPhistory → | COM | 9.21% | $7M | 980.7K |
| 5 | EPSNEPSILON ENERGY LTDhistory → | COM | 9.21% | $7M | 1.38M |
| 6 | BNYBANK NEW YORK MELLON CORPhistory → | COM | 8.52% | $6M | 125.0K |
| 7 | SPYSPDR S&P 500 ETF TRhistory → | TR UNIT | 5.70% | $4M | 10.0K |
| 8 | NEMNEWMONT CORPhistory → | COM | 5.48% | $4M | 65.0K |
| 9 | VERSO CORP | CL A | 4.43% | $3M | 188.0K |
| 10 | CREDIT SUISSE GROUP | SPONSORED ADR | 4.19% | $3M | 300.0K |
| 11 | EXECHESAPEAKE ENERGY CORPhistory → | COM | 3.66% | $3M | 53.0K |
| 12 | CICIGNA CORP NEWhistory → | COM | 3.63% | $3M | 11.5K |
| 13 | KNLKNOLL INChistory → | COM NEW | 1.73% | $1M | 50.0K |
| 14 | BFSSAUL CTRS INChistory → | COM | 1.51% | $1M | 25.0K |
| 15 | LUMOS PHARMA INC | COM | 0.67% | $500,000 | 50.0K |
| 16 | ATNIATN INTL INC | COM | 0.54% | $409,000 | 9.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $74M | 14 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $48M | 12 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $56M | 12 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $63M | 15 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $43M | 13 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $43M | 12 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $56M | 16 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $41M | 11 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $56M | 16 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $44M | 15 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $31M | 10 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $49M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 11 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $54M | 17 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $50M | 12 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $51M | 11 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $54M | 7 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $63M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $88M | 17 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $75M | 16 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $66M | 11 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $65M | 10 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $74M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $91M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 13 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $178M | 19 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $130M | 21 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $130M | 25 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $106M | 30 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.